Athira Pharma, Inc. (ATHA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
18706 North Creek Parkway
Bothell, WA 98011
United States of America (the)
Phone
425 620 8501
Website
Sector
Healthcare
Industry
Biotechnology
Employees
26
First IPO Date
September 18, 2020
| Name | Title | Pay | Year Born |
| Mark J. Litton | President, Chief Executive Officer & Director | 1.05M | 1968 |
| Kevin Church | Chief Scientific Officer | 680,085 | 1985 |
| Mark F. Worthington | General Counsel, Chief Compliance Officer & Corporate Secretary | 681,523 | 1966 |
| Robert Renninger | Chief Financial Officer | 0 | 1984 |
| Julie Rathbun | Head of Investor Relations | 0 | N/A |
| Javier San Martin | Chief Medical Officer | 0 | 1965 |
Athira Pharma, Inc., a biopharmaceutical firm in advanced clinical development and based in Bothell, Washington, focuses on creating small molecule treatments designed to revitalize neuronal function and decelerate neurological decline. Its primary therapeutic candidate, ATH-1017, is a unique small molecule that modulates HGF/MET and is capable of crossing the blood-brain barrier. This compound is currently undergoing a Phase 3 clinical trial (LIFT-AD) and a Phase 2 clinical trial (ACT-AD) for Alzheimer's disease. Additionally, ATH-1017 is in Phase 2 clinical trials for Parkinson's disease. The company also has several product candidates in earlier, preclinical stages of development, including ATH-1019 for conditions affecting the peripheral nervous system and ATH-1020 for neuropsychiatric disorders. Founded in 2011, the organization was known as M3 Biotechnology, Inc. until it rebranded to Athira Pharma, Inc. in April 2019.